IRIS

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with ad-vanced melanoma treated with nivolumab / Capone, M; Giannarelli, D; Mallardo, D; Madonna, G; Festino, L; Grimaldi, Am; Vanella, V; Si-meone, E; Paone, M; Palmieri, G; Cavalcanti, E; Caracò, C; Ascierto, Pa. - In: JOURNAL FOR IMMUNOTHERAPY OF CANCER. - ISSN 2051-1426. - 16:(2018). [10.1186/s40425-018-0383-1]

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with ad-vanced melanoma treated with nivolumab

Palmieri G
Investigation
;
2018-01-01
2018
WOS:000438906000003
16
2-s2.0-85050131572
Esperti anonimi
Sì
Internazionale
Capone, M; Giannarelli, D; Mallardo, D; Madonna, G; Festino, L; Grimaldi, Am; Vanella, V; Si-meone, E; Paone, M; Palmieri, G; Cavalcanti, E; Caracò, C...espandi
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with ad-vanced melanoma treated with nivolumab / Capone, M; Giannarelli, D; Mallardo, D; Madonna, G; Festino, L; Grimaldi, Am; Vanella, V; Si-meone, E; Paone, M; Palmieri, G; Cavalcanti, E; Caracò, C; Ascierto, Pa. - In: JOURNAL FOR IMMUNOTHERAPY OF CANCER. - ISSN 2051-1426. - 16:(2018). [10.1186/s40425-018-0383-1]
info:eu-repo/semantics/article
1 Contributo su Rivista::1.1 Articolo in rivista
262
13
none
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/245047
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 425
  • ???jsp.display-item.citation.isi??? 417
social impact